Articles by Adam Feuerstein
Two companies developing a therapy for a rare blood cancer have reached an agreement with the Food and Drug Administration that walked back the agencys main reason for rejecting the drug in January.Β ...
The drugmaker Erasca said Monday that its RAS-targeting pill shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced non-small cell lung cancer, results thaοΏ½...
This is the online version of Adams Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign upΒ hereΒ to get it delivered to their inbox.
Adam Feuerstein/STAT
SAN FRANCISCO The s...
This story first appeared in Adams Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign upΒ hereΒ to get it delivered to their inbox.
Welcome back, everyone! I missed you all. ...
It took 27 years, but Cytokinetics secured its first U.S. drug approval.
On Friday, the Food and Drug Administration cleared the new medicine, called Myqorzo, to treat patients with obstructive hypeοΏ½...
In an exceptional year for biotech and pharma, there were so many outstanding CEOs, I couldnt single out just one for my 2025 Best Biopharma CEO honor.
Here are this years winners:Β
2025 has been t...
